Based on the clinical course and literature review, we believe that the hypoglycemia in this case was due to a drug interaction, caused by inhibition of CYP2C9 by bucolome and competitive inhibition of CYP2C9 by warfarin, which affected the pharmacokinetics of glimepiride. Here, CYP2C9 is linked to Hypoglycemia.